Universidad de los Andes

Search results

• University of los Andes Researcher Publishes Findings in Pharmaceutics (Oral Administration as a Potential Alternative for the Delivery of Small Extracellular Vesicles)

  Francisca Alcayaga-Miranda & Maroun Khoury

  13/03/23

  1 item of Media coverage

  Press/Media

• Manuel Pellegrini: "I try to be apolitical. Football unites, the fan next door doesn't matter if he is communist, right-wing, republican..."

  Manuel Pellegrini

  5/03/23

  1 item of Media coverage

  Press/Media

• Manuel Pellegrini: "I try to be apolitical. Soccer unites, the fan next to me doesn't matter if he is a communist, right-winger, republican...".

  Manuel Pellegrini

  4/03/23

  1 item of Media coverage

  Press/Media

• Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma

  Mauricio Burotto

  3/03/23

  2 items of Media coverage

  Press/Media

• U.S. Clinical Trial: Universidad de los Andes, Chile Listed a New Clinical Trial to Study "Ready-to-use" Intra-articular Formulation of Mesenchymal Stromal Cells (PANLAR-II)

  Fernando E. Figueroa

  2/03/23

  1 item of Media coverage

  Press/Media

• Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC

  Mauricio Burotto

  28/02/23

  1 item of Media coverage

  Press/Media

• Nivolumab Plus Cabozantinib Demonstrates Positive Results for Renal Cell Carcinoma

  Mauricio Burotto

  27/02/23

  1 item of Media coverage

  Press/Media

• Everyone knows everyone: the tangle of networks linking the Constitutional Council's experts

  Jaime Arancibia

  23/02/23

  1 item of Media coverage

  Press/Media

• Nivolumab-plus cabozantinib improves outcomes in advanced renal cell carcinoma

  Mauricio Burotto

  23/02/23

  2 items of Media coverage

  Press/Media

• Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma

  Mauricio Burotto

  21/02/23

  1 item of Media coverage

  Press/Media

• Nivolumab/cabozantinib shows improvements in long-term survival for RCC

  Mauricio Burotto

  19/02/23

  2 items of Media coverage

  Press/Media

• How Covid vaccination is coming in 2023

  Maria Luz Endeiza

  18/02/23

  1 item of Media coverage

  Press/Media

• Positive results for Ipsen 's Cabometyx in combination with nivolumab

  Mauricio Burotto

  17/02/23

  1 item of Media coverage

  Press/Media

• Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms

  Mauricio Burotto

  16/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

  Mauricio Burotto

  13/02/23 → 16/02/23

  5 items of Media coverage

  Press/Media

• Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

  Mauricio Burotto

  16/02/23

  1 item of Media coverage

  Press/Media

• Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

  Mauricio Burotto

  15/02/23

  1 item of Media coverage

  Press/Media

• Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC

  Mauricio Burotto

  15/02/23

  1 item of Media coverage

  Press/Media

• How many are retired, where are they playing: a look back at the Golden Generation that won the 2015 Copa América

  Manuel Pellegrini

  15/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  13/02/23 → 14/02/23

  56 items of Media coverage

  Press/Media

• Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  13/02/23 → 14/02/23

  18 items of Media coverage

  Press/Media

• Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  14/02/23

  2 items of Media coverage

  Press/Media

• Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023

  Mauricio Burotto

  14/02/23

  1 item of Media coverage

  Press/Media

• Ipsen announces CheckMate 3-yr follow-up aRCC results

  Mauricio Burotto

  14/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma

  Mauricio Burotto

  14/02/23

  1 item of Media coverage

  Press/Media